DEERFIELD, IL--(Marketwire - Dec 3, 2012) - Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that RAYOS ® (prednisone) delayed release tablets are now available to U.S. physicians to treat a broad ...
DEERFIELD, Ill., July 26, 2012 /PRNewswire/ -- Horizon Pharma, Inc., (NASDAQ: HZNP) announced today that the U.S. Food and Drug Administration (FDA) has approved RAYOS ® (prednisone) delayed-release ...
RAYOS (prednisone) 5mg delayed-release tablets Horizon Pharma announced that the FDA has approved Rayos (prednisone) delayed-release tablets for the treatment of rheumatoid arthritis (RA), polymyalgia ...
RAYOS approved for key rheumatology indications such as Rheumatoid Arthritis, Polymyalgia Rheumatica, Psoriatic Arthritis and Ankylosing Spondylitis. DEERFIELD, Ill., July 26, 2012 /PRNewswire/ -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results